Not content with a $1.2 billion licensing deal for Biohaven Pharma's oral migraine therapy rimegepant, Pfizer has just offered to buy the company outright – for a cool $11.6 billion. Pfizer's ...

Shares of Biohaven Ltd. climbed 13% premarket on Monday after the biotech company said its treatment for a rare neurological ...

Shares of Biohaven (BHVN) gained in morning trade on Tuesday after the company’s director John W. Childs acquired shares worth $1.04 million on Monday. According to Biohaven’s U.S. Securities ...

Get Our Latest Research Report on Biohaven Biohaven Price Performance Biohaven stock opened at $38.30 on Friday. The firm’s 50-day moving average is $39.65 and its two-hundred day moving average ...

Merus has announced a research collaboration and license agreement with Biohaven. Under the agreement, Biohaven and Merus will to co-develop three antibody-based therapies. Get real-time earnings ...

$60,000 of BIOHAVEN PHARMACEUTICALS INC. lobbying was just disclosed, from Q4 of 2024, in a new Lobbying Disclosure Act filing. This included lobbying on issues like: "Policies related to drug ...

Biohaven Ltd. is a global clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies for people with neurological and ...

Check Out Our Latest Analysis on BHVN Biohaven Stock Performance Shares of NYSE:BHVN opened at $38.40 on Monday. Biohaven Ltd. has a 52 week low of $26.80 and a 52 week high of $62.21. The firm ...

(RTTNews) - Biohaven Ltd. (BHVN) and Merus N.V. (MRUS) announced a research collaboration and licensing agreement aimed at co-developing three innovative bispecific antibody drug conjugates (ADCs).

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...